TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kymera Therapeutics
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics initiated dosing in its BROADEN2 Phase 2b clinical trial for KT-621, an oral STAT6 degrader targeting moderate to severe atopic dermatitis. The company expects to report trial data by mid-2027 and is also preparing for a Phase 2b asthma trial in early 2026.

Insights
GRABW   positive

Strong growth in multiple segments (23% delivery growth, 39% fintech growth), expanding middle-class market, raised full-year guidance, positive analyst ratings (7 Buy, 5 Hold), and institutional ownership of 55% support a bullish outlook


KYMR   positive

The company is advancing a novel drug candidate (KT-621) across multiple clinical trials, demonstrating progress in developing a potential first-in-class treatment for immunological diseases